Browsing Tag
AIM
60 posts
Pri0r1ty Intelligence resumes trading as PR1 tests investor appetite for SME AI tools
Find out how Pri0r1ty Intelligence’s AIM return, first revenue and AI platform strategy are reshaping PR1 stock and SME technology sentiment.
Virgin Wines cuts FY26 expectations as VINO faces consumer demand and cost pressure
Find out how Virgin Wines’ FY26 loss warning, new Preston warehouse and VINO stock slump are reshaping its online wine growth story.
Avacta (AIM: AVCT) raises £9m at no discount days after ASCO cancer data
Avacta (AIM: AVCT) raised £9m at no discount just before a 30 June bond trigger, days after AVA6000 cancer data. Is this a turnaround or another clock ticking?
Rainbow Rare Earths (AIM: RBW) eyes a US listing as Phalaborwa nears its DFS
China refines almost every rare earth on Earth. Rainbow Rare Earths (AIM: RBW) wants to make them from waste, and a US listing is now in play.
Cornish Metals advances South Crofty drilling, but can Roskear lift the UK tin revival story?
South Crofty has policy momentum. Roskear assays will test whether Cornish Metals can add real resource upside to the UK tin revival.
EnSilica (AIM: ENSI) wins $75m contract as German automotive chip deal strengthens recurring revenue outlook
EnSilica’s $75m German automotive chip deal strengthens ENSI’s revenue outlook. Find out what it means for investors and the sector today!
Serabi Gold (AIM:SRB) shares rise as Q1 production, cash and profit strengthen Brazil mining outlook
Find out how Serabi Gold’s Q1 profit surge, debt-free balance sheet and Coringa ramp-up could reshape AIM investor sentiment.
Is Helium One (HE1.L) finally moving from helium hype to proof?
Helium One has helium, licences and first gas. The harder test is whether HE1.L can secure a partner before dilution fears return.
ImmuPharma at 4p is a P140 licensing bet: What IMM retail investors should know
ImmuPharma targets a P140 licensing deal in 2026 with cash to H2 2028. Here is what IMM retail investors need to weigh before chasing the small-cap biotech.
AVCT entry at 86p is a bet on AVA6103: What Avacta Group investors should know
Avacta Group sets up a binary AVA6103 readout for late H2 2026. Here is what AVCT retail investors need to weigh before the data lands and runway runs.